Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Our management team and board of directors has extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. Our strategy is to leverage this experience to in-license, acquire, develop and commercialize products that we believe can be successful in the global dermatology marketplace. Our portfolio of five product candidates, all new molecular entities with relevant mechanism of actions in skin diseases, targets significant market opportunities.
We believe that medical dermatology represents a particularly attractive segment of the biopharmaceutical industry for multiple reasons:
- Dermatology encompasses a large, growing, specialty market supported by strong patient demand.
- The dermatology market is primed for innovation with significant development and commercial opportunities.
- The development of dermatology products can be efficient in terms of time and cost.
- The needs of dermatologists and their patients have been underserved as a result of the significant consolidation of dermatology-focused companies.
Accordingly, these industry dynamics present a unique opportunity for Brickell to become a leader in dermatology product development, and we plan to capitalize on that opportunity by developing our pipeline of novel product candidates to address rapidly growing skin indications where new therapies will be welcomed in the marketplace.